Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
Scientific Community
Become a Member | Sign in
Home>News>This Article

Researchers Develop a Method to Evaluate Variations Identified in Breast Cancer Susceptibility Genes

Published: Tuesday, July 08, 2008
Last Updated: Tuesday, July 08, 2008
Bookmark and Share
The researchers believe that the new test could become a useful and viable tool for genetic counselors, and may have implications beyond cancer.

Using mouse embryonic stem cells, researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, have developed a new method to evaluate which mutations, or changes, in a gene known to increase breast cancer susceptibility, may lead to cancer.

The new test, called a functional assay, is more comprehensive and reliable than most current methods. This new test could become a useful and viable tool for genetic counselors, and may have implications beyond cancer.

The researchers believe that this test could also be useful for analyzing mutations found in other human disease-related genes. The results of this research will be published in the August 2008 issue of "Nature Medicine" and appear online July 6, 2008.

The proteins produced by the BRCA1 (BReast CAncer gene 1) and BRCA2 genes normally help to maintain the integrity of the cell's genetic material and function as tumor suppressors.

For over a decade, it has been known that alterations or defects in BRCA1, BRCA2, and their associated proteins are linked to increased risks of early onset familial breast and ovarian cancers. Studies have shown that a woman who has a mutation in one of these genes has a 35 to 85 percent risk of developing breast cancer by age 70, compared to the average American woman's lifetime risk of 12.3 percent.

Some individuals who want to know if they have inherited a mutation in a gene such as BRCA1 or BRCA2 that will increase their risk of developing breast or ovarian cancer are now choosing to go for genetic testing. Such tests can provide reassuring information to those who do not have harmful mutations, and can be helpful to those with harmful BRCA1 or BRCA2 mutations because when they know that they are at risk, they can work with their physicians to find the course of action that is best for them.

"However, think about those individuals who are tested and find out that they have an unclassified [minor or previously unknown] change in these genes, and they do not know what it means," said senior author Shyam Sharan, Ph.D. of the NCI's Center for Cancer Research.

"There is reason to believe that a significant number of women fall into this category, and our assay is likely to improve our understanding of unclassified mutations because it allows for analysis of all types of BRCA2 mutations," he added.

The new test looks for the functional significance of variations in BRCA2 using mouse embryonic stem cells. Mouse Brca2 is essential for the viability of mouse embryonic stem cells, and the assay is based on the ability of the human BRCA2 gene to complement the loss of the Brca2 gene in the mouse cells.

When introduced into a Brca2-deficient mouse embryonic stem cell in laboratory experiments, functionally normal human BRCA2 variants can compensate for the mouse Brca2 deficiency. On the other hand, harmful or deleterious variants of human BRCA2 do not have this ability, leading to their identification in this test.

Lead author of this paper, Sergey Kuznetsov, Ph.D., generated a set of cells in which one copy of the BRCA2 gene is inactivated or knocked out, and the other remains active but can be inactivated later. The researchers then introduced human genetic material, taking care to maintain all of the coding sequences and regulatory elements of the BRCA2 gene.

When genetic material with neutral variants of human BRCA2 was introduced, the researchers were able to subsequently remove the remaining copy of the mouse BRCA2 without compromising the viability of the cell.

The addition of genetic material with harmful variants, however, resulted in either cell death or deficient DNA repair. Therefore, the assay can be used to examine genetic material with minor or previously unknown variants. If a human variation does not alter the function of the mouse BRCA2, the risk of developing cancer is probably the same as that of the rest of the population, but if the change is disruptive, the risk of developing cancer increases significantly. The researchers are also working on development of a similar test for BRCA1 variants.

The researchers hope that other human disease gene functions may be evaluated in a similar fashion using this type of analysis. This represents an efficient method of analysis in which three to five gene variants can be analyzed in two to three months.

The researchers have provided preliminary validation of the functional assay by testing 17 variants, and have established the reproducibility of the technique for BRCA2. They caution, however, that only when this technique is FDA approved for use in a clinical setting will it be available to patients for diagnostic testing.

The technology behind this new assay is available for further research, and Dr. Sharan's laboratory is interested in collaborating with commercial organizations to further develop it as a product under the appropriate NIH agreements.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

2011 Biospecimen Research Network (BRN) Symposium
The National Cancer Institute's (NCI) Biospecimen Research Network Symposium, "Advancing Cancer Research Through Biospecimen Science," will be held March 28-29, 2011, at the Bethesda North Marriott Hotel & Conference Center in Bethesda, MD
Friday, January 07, 2011
Scientists Identify Markers on Human Breast Cancer Cells Linked to Development of a Form of Breast Cancer
The scientists named these human cells with tumor-forming ability in mice, xenograft-initiating cells, or XIC.
Friday, May 21, 2010
Drug for Multiple Myeloma Demonstrated to Extend Disease-Free Survival
Patients receiving lenalidomide following a blood stem cell transplant had their cancer kept in check longer than placebo receiving patients.
Thursday, December 24, 2009
Cancer Immunotherapy Can Use Small Numbers of Stem-Like Immune Cells to Destroy Large Tumors in Mice
New approach to stimulating immune cells enhances their anticancer activity, resulting in a powerful anti-tumor response in mice.
Friday, June 26, 2009
Mouse Studies Show Gene Therapy Method Holds Promise in Targeting Tumor Blood Vessels for Destruction
Cancer researchers develop method for delivering a therapeutic gene specifically to the blood vessels of tumors in mice.
Thursday, December 18, 2008
Method of Gene Therapy Alters Immune Cells for Treatment of Advanced Melanoma
Technique may also apply to other common cancers.
Friday, September 01, 2006
Scientific News
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
CRI Identifies Emergency Blood-formation Response
Researchers report that when tissue damage occurs, an emergency blood-formation system activates.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
The Life Story of Stem Cells
A model analyses the development of stem cell numbers in the human body.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Advancing Genome Editing of Blood Stem Cells
Genome editing techniques for blood stem cells just got better, thanks to a team of researchers at USC and Sangamo BioSciences.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Towards Patient-Specific Drug Screening
A new breakthrough by the 3D stem cell printing team at Heriot-Watt could pave the way to individually tailored drug testing regimes, both reducing the need for animal testing and ensuring that patients receive drugs which are most effective for their individual needs.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos